761 related articles for article (PubMed ID: 25464159)
1. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.
Dodick DW; Turkel CC; DeGryse RE; Diener HC; Lipton RB; Aurora SK; Nolan ME; Silberstein SD
J Pain; 2015 Feb; 16(2):164-75. PubMed ID: 25464159
[TBL] [Abstract][Full Text] [Related]
2. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
3. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
Cady RK; Schreiber CP; Porter JA; Blumenfeld AM; Farmer KU
Headache; 2011 Jan; 51(1):21-32. PubMed ID: 21070228
[TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
5. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.
Silberstein S; Lipton R; Dodick D; Freitag F; Mathew N; Brandes J; Bigal M; Ascher S; Morein J; Wright P; Greenberg S; Hulihan J
Headache; 2009 Sep; 49(8):1153-62. PubMed ID: 19719543
[TBL] [Abstract][Full Text] [Related]
6. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
[TBL] [Abstract][Full Text] [Related]
8. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
[TBL] [Abstract][Full Text] [Related]
9. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
10. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
[TBL] [Abstract][Full Text] [Related]
11. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
Mathew NT; Jaffri SF
Headache; 2009; 49(10):1466-78. PubMed ID: 19912346
[TBL] [Abstract][Full Text] [Related]
12. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
[TBL] [Abstract][Full Text] [Related]
13. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
Dodick DW; Silberstein SD; Lipton RB; DeGryse RE; Adams AM; Diener HC
Cephalalgia; 2019 Jul; 39(8):945-956. PubMed ID: 31112399
[TBL] [Abstract][Full Text] [Related]
14. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
Frampton JE
Drugs; 2012 Apr; 72(6):825-45. PubMed ID: 22468643
[TBL] [Abstract][Full Text] [Related]
15. Development of onabotulinumtoxinA for chronic migraine.
Whitcup SM; Turkel CC; DeGryse RE; Brin MF
Ann N Y Acad Sci; 2014 Nov; 1329():67-80. PubMed ID: 25399521
[TBL] [Abstract][Full Text] [Related]
16. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
Diener HC; Dodick DW; Aurora SK; Turkel CC; DeGryse RE; Lipton RB; Silberstein SD; Brin MF;
Cephalalgia; 2010 Jul; 30(7):804-14. PubMed ID: 20647171
[TBL] [Abstract][Full Text] [Related]
17. The impact of topiramate on health-related quality of life indicators in chronic migraine.
Dodick DW; Silberstein S; Saper J; Freitag FG; Cady RK; Rapoport AM; Mathew NT; Hulihan J; Crivera C; Rupnow MF; Mao L; Finlayson G; Greenberg SJ
Headache; 2007; 47(10):1398-408. PubMed ID: 18052949
[TBL] [Abstract][Full Text] [Related]
18. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.
Lipton RB; Rosen NL; Ailani J; DeGryse RE; Gillard PJ; Varon SF
Cephalalgia; 2016 Aug; 36(9):899-908. PubMed ID: 27288354
[TBL] [Abstract][Full Text] [Related]
19. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.
Diener HC; Agosti R; Allais G; Bergmans P; Bussone G; Davies B; Ertas M; Lanteri-Minet M; Reuter U; Sánchez Del Río M; Schoenen J; Schwalen S; van Oene J;
Lancet Neurol; 2007 Dec; 6(12):1054-62. PubMed ID: 17988947
[TBL] [Abstract][Full Text] [Related]
20. Implications of current clinical trials focused on medication overuse and therapeutic prophylaxis.
Aurora SK
Headache; 2011; 51 Suppl 2():93-100. PubMed ID: 21770931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
